A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin?s lymphoma: investigation of the current protocol through theoretical modelling results | Zendy

Benjamin Ribba | Zendy; Karen Marron | Zendy; Zvia Agur | Zendy; Tomás Alarcón | Zendy; Philip K. Maini | Zendy

Open Access

A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin?s lymphoma: investigation of the current protocol through theoretical modelling results

Author(s) -

Benjamin Ribba,

Karen Marron,

Zvia Agur,

Tomás Alarcón,

Philip K. Maini

Publication year - 2004

Publication title -

bulletin of mathematical biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.693

H-Index - 89

eISSN - 1522-9602

pISSN - 0092-8240

DOI - 10.1016/j.bulm.2004.06.007

Subject(s) - doxorubicin , lymphoma , pharmacodynamics , pharmacokinetics , hodgkin lymphoma , medicine , pharmacology , oncology , cancer research , chemotherapy

Doxorubicin treatment outcomes for non-Hodgkin's lymphomas (NHL) are mathematically modelled and computationally analyzed. The NHL model includes a tumor structure incorporating mature and immature vessels, vascular structural adaptation and NHL cell-cycle kinetics in addition to Doxorubicin pharmacokinetics (PK) and pharmacodynamics (PD). Simulations provide qualitative estimations of the effect of Doxorubicin on high-grade (HG), intermediate-grade (IG) and low-grade (LG) NHL. Simulation results imply that if the interval between successive drug applications is prolonged beyond a certain point, treatment will be inefficient due to effects caused by heterogeneous blood flow in the system.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research